Russia’s Tomsk keen to garner share of Indian pharma market, as its business delegation visits 3 Indian cities

Russia’s Tomsk keen to garner share of Indian pharma market, as its business delegation visits 3 Indian cities

Russia’s Tomsk region known for its pharmaceuticals and chemicals have evinced interest for collaborations and joint ventures with Indian companies. A business delegation of small and medium companies from the Tomsk Region, Russia was here in Bengaluru, Mumbai and New Delhi to ascertain the growth prospects.

With Russia's official succession to the WTO, the customs duties imposed on drugs have dropped from 15 percent to about 6.5 per cent. The two countries are  already exploring the possibility of a Free Trade Agreement to give a fillip to bilateral trade from the existing $6 billion, which is less than one per cent of India’s total foreign trade.

The business delegation organized  by the Tomsk Chamber of Commerce and Industry, Tomsk Region, Russia was in India where along with the Federation of Indian Chamber of Commerce (FICCI) state branches were looking to discover new opportunities of mutually beneficial cooperation with potential Indian pharma.

Now India is looking to attract investments in the Delhi Mumbai Industrial Corridors, the New Manufacturing and Investment Zones and increase pharmaceutical export to Russia, noted sources.

Out of the ten member delegation, that were in Karnataka recently,  two specific companies:  Zeleynaya engaged in herbal tea production was scouting for a market here.  Corporate Medicine Center Ltd. is specialised safety-security protection and medicine services for  enterprises, as well as  comprehensive clinical care. This company focuses on employee’s health. Therefore it was looking for an opportunity in India because it was known for its large industrial hubs, according to officials.

It is gathered that the  representative of the Corporate Medicine Center had said that since it was known to provide  highly professional medical services for corporate houses and industrial hubs, it was looking to chip in emergency medicine, working conditions estimation and consult services for safe working conditions offer first-aid training.

For Indian pharma, Russia is a key market for branded formulations in anti infectives, life style disorders, dermatology, nephrology and oncology. However, an issue of non-tariff barriers that are in place especially in drugs registration and research and development of new drugs created difficult for global companies to have an easy access to the Russia market.

In 2012-13, the Union government worked to further strengthen the association with Russia for enhancing trade of pharmaceuticals.

The new Government too is keen to iron out issues and make Russia an easy to trade region for pharmaceuticals.

In addition, companies also face  impediments like access to location in Russia, language barriers, inadequate transit facilities, insufficiency of data on business opportunities and lack of direct and regular interaction among the business entities, pointed out members of Karnataka Drugs and Pharmaceuticals Manufacturers Association.

The leading companies in India present in the region are Dr. Reddy’s Labs, Shreya Lifesciences, Aurobindo Pharma, Lupin, Sun Pharma, Ranbaxy among others.  From Karnataka, Biocon, Micro Labs, Bal Pharma are also present in Russia.

Source:http://www.pharmabiz.com/NewsDetails.aspx?aid=84933&sid=1

06 Nov-

Eli Lilly gets FDA approval for gastric cancer combination drug

Eli Lilly and Company has received the US Food and Drug Administration (FDA) approval for Cyramza (ramucirumab) in combination with paclitaxel (a type of chemotherapy) to treat advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma.

The approval of this combination regimen is for patients whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

The FDA approval is based on data from a multinational, randomized, double-blinded, placebo-controlled Phase III RAINBOW trial, which compared Cyramza plus paclitaxel to placebo plus paclitaxel.

The trial's efficacy endpoints included the major efficacy outcome measure of overall survival and the supportive efficacy outcome measures of progression-free survival and objective response rate.

Lilly Oncology senior vice-president, product development and medical affairs Richard Gaynor said: "This FDA approval of CYRAMZA represents another milestone for people battling this devastating and difficult-to-treat disease.

"Lilly is pleased to continue delivering on its commitment to provide new treatment options to people living with cancer and those who care for them."

The company said that labeling for Cyramza contains a Boxed Warning regarding increased risk of hemorrhage, including severe and sometimes fatal hemorrhagic events.

Source:http://www.pharmaceutical-business-review.com/news/eli-lilly-gets-fda-approval-for-gastric-cancer-combination-drug-061114-4429834

TIST develops laser device for cancer, eye treatment

The Toc-H Institute of Science and Technology (TIST) here has developed an affordable laser device to be used in oncology, ophthalmology and other industrial applications.

TIST is a popular engineering college and it has taken the institute three years of research and development in laser technology to come up with this device with the support of the Union Department of Science and Technology (DST),

According to TIST founder director K. Varghese, the institution had developed the device indigenously at a time when the country was heavily dependent on imports. Except for the diamond industry in Gujarat, this laser device is not manufactured commercially in India.

"We are taking steps for the commercial launch of the device which has immense utility in the rapidly expanding medical and other industrial research in the country," he said.

"This is extensively used in ophthalmology and oncology. In cosmetic medicine, it is used for laser hair removal and for the treatment of minor vascular defects such as spider veins on the face and legs. In dentistry, these lasers are used for soft tissue surgeries in the oral cavity. It is also used in the automotive industry and in manufacturing for engraving, etching, or marking a variety of metals and plastics and by the military as laser range finders," said S.K.S. Nair, TIST professor.

Source:http://zeenews.india.com/news/health/health-news/tist-develops-laser-device-for-cancer-eye-treatment_1494948.html

Radiological Precision Labs (India) Pvt. Ltd., to become National Distributor of FLUKE Biomedical in India

Radiological Precision Labs (India) Pvt. Ltd. (RPL), the first company to get authorization from Atomic Energy Regulatory Board (AERB) for providing quality assurance (QA) services in diagnostic radiology, today announced national distributorship of FLUKE Biomedical for its Radiation Monitoring Systems Line in India. FLUKE Biomedical is a leader in manufacturing of biomedical test & simulation products and is known for some of the most trusted and accurate diagnostic imaging, radiation safety, and oncology quality-assurance solutions for regulatory compliance.

Subsequent to Unfors RaySafe AB, Sweden being acquired by FLUKE Biomedical, the present team of Unfors RaySafe India Pvt. Ltd. (a wholly owned subsidiary of Unfors RaySafe AB, Sweden) will become part of RPL team. This will bring in their market leading capability, technical expertise and customer relationships to the RPL team.

RPL has in-house capability to perform verification of QA and radiation safety instruments with strong technical collaboration with Unfors RaySafe AB, Sweden. This provides an excellent option to the customers, as they do not have to send their instruments to parent companies for verification and repairs. The customer can now avail QA products, QA services and QA product after-sales support under one umbrella. With the qualified staff, RPL can provide adequate training to the users of QA products.

Speaking on the occasion Mr. Rahul Shanghai, Director, Radiological Precision Labs (India) Pvt. Ltd. said: “RPL was embarked with an objective to provide quality assurance services for radiation equipment and now, in a decade it has outstanding customer rapport with almost all the Original equipment manufacturers (OEMs) and corporate hospitals in India. This relationship will now be extended to provide radiation safety & QA products through various channel partners, AERB certified engineers and its top-notch after-sales services.”   

RPL will cater to wide range of clientele from OEMs, x-ray equipment suppliers, service providers to hospitals.

"It is a win-win situation for both FLUKE Biomedical & RPL, as it will provide them pan-India presence, stronger sales drive and broader visibility of their product offerings." added Mr. Sanghavi.

About Radiological Precision Labs (India) Pvt. Ltd:

Radiological Precision Labs (India) Pvt. Ltd., is primarily a service providing company, dedicated to offer quality assurance services for radiation generating equipment.

With its quality assurance test services, it helps healthcare institutes and industries in implementation of functional quality assurance programme, which suffices quality standards as per regulatory and quality benchmarking councils.

RPL also provides in-house verification and repair of QA products.